Tranzyme Pharma to Report Second Quarter 2011 Financial Results

RESEARCH TRIANGLE PARK, N.C., Aug. 2, 2011 (GLOBE NEWSWIRE) — Tranzyme Pharma (Nasdaq:TZYM), today announced that it will report second quarter 2011 financial results after the close of the market on Thursday, August 11, 2011. In connection with this announcement, the Company will host a conference call on Friday, August 12, 2011 at 8:30 A.M. ET to discuss these financial results.

To participate in the live call, please dial (877) 670-9784 (U.S. and Canada) or (970) 315-0430 (international), five to ten minutes prior to the start of the call. A live audio webcast will also be available in the “Investors” section of the Tranzyme Pharma website, www.tranzyme.com.

A replay of the conference call will be available beginning August 12, 2011 at 11:30 A.M. ET and ending on August 19, 2011. Investors may listen to the replay by dialing (855) 859-2056 (U.S. and Canada) or (404) 537-3406 (international), with the passcode 84628669.�The webcast will also be archived for on-demand listening for 30 days at www.tranzyme.com.

About Tranzyme Pharma

Tranzyme Pharma is a late-stage biopharmaceutical company focused on discovering, developing and commercializing novel, mechanism-based therapeutics for the treatment of upper gastrointestinal (GI) motility disorders. While approximately 20 percent of adults worldwide are affected by these persistent and recurring conditions which disrupt the normal movement of food throughout the GI tract, currently there are a limited number of safe and effective treatment options. Tranzyme is developing an intravenous drug, ulimorelin, for patients in acute (hospital-based) settings, as well as an oral drug (TZP-102) for chronic conditions. Ulimorelin is currently in Phase 3 clinical trials and TZP-102 is entering Phase 2b. Together these product candidates target a significant underserved market. By leveraging its proprietary drug discovery technology, Tranzyme is committed to pursuing first-in-class medicines to address areas of significant unmet medical needs.

Tranzyme has two strategic partnerships in place: a license agreement with Norgine B.V. for the co-development and commercialization of ulimorelin in Europe and other select territories, and a technology collaboration with Bristol-Myers Squibb Company focused on the identification and optimization of novel drug compounds for certain targets of interest to BMS.

Further information about Tranzyme Pharma can be found on the Company’s web site at www.tranzyme.com

The Tranzyme, Inc. logo is available at http://ping.fm/FWwvq

CONTACT: Corporate Inquiries:
         Susan P. Sharpe
         Corporate Communications Manager
         (919) 313-4761
         ssharpe@tranzyme.com

         Investor Inquiries:
         David Carey
         Lazar Partners, Ltd.
         (212) 867-1768
         dcarey@lazarpartners.com

News

http://bit.ly/oQglcN